Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals PLC has announced the departure of Dmitry Zamoryakhin, its Chief Scientific Officer and Chief Medical Officer, as of July 4, 2024. The company has engaged an interim consultant to take over the Chief Medical Officer role while they search for a permanent replacement. This corporate update is set to impact the company’s registration statements and investor considerations.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
